Premature ejaculation is the most common form of male sexual dysfunction affecting roughly 1 in 3 men between the ages of 18 to 59 years old. Currently, in the United States, pharmacological treatment therapies for premature ejaculation are administered as a cream or spray. Treating premature ejaculation with local anesthetic therapies has been restricted due to a lack of efficacy in previous studies.
Publication Number: PD69-02
Double-Blind, Randomized Controlled Trial of Topical 4% Benzocaine Wipes for Management of Premature Ejaculation: Interim
An analysis was conducted on 21 adult men in a heterosexual, monogamous relationship with premature ejaculation. Premature ejaculation was defined by self-reported poor control over ejaculation, personal distress related to ejaculation, and an average intravaginal ejaculatory latency time (IELT) at, or below, two minutes. The men were randomized with 15 undergoing the treatment and 6 receiving the placebo.
• After two months, men undergoing the treatment had significant improvement in IELT than men on placebo.
• A greater proportion of men in the treatment group achieved IELT of at least two minutes vs. men on placebo.
• Compared to placebo, men in the treatment group reported greater improvement in distress relating to intercourse, control of ejaculation and satisfaction with sexual intercourse over the study period.
“This study is encouraging in demonstrating a new and innovative way to reduce the symptoms of premature ejaculation,” said Dr. Köhler. “Premature ejaculation can cause a variety of issues related to negative feelings and emotions that can lead to problems with sexual relationships. This data shows topical 4% benzocaine wipes is a promising therapy to treat the most common form of sexual dysfunction among men.”